Get informed when a big investor buys or sells
+ Follow-16.97%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
LabTurbo Biotech (7725.TWO) currently reports a ROE of -16.97%. That is above the Healthcare sector average of -100.59%. Use the charts on this page to explore LabTurbo Biotech's ROE history and peer comparisons.
LabTurbo Biotech's ROE of -16.97% is higher than the Healthcare sector average of -100.59%. That is roughly 83.1% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but LabTurbo Biotech's current -16.97% should be judged against Healthcare norms (sector average: -100.59%) and against 7725.TWO's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -16.97%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -100.59%. From there, open related valuation or income-statement pages for LabTurbo Biotech, and consider following 7725.TWO for alerts when major investors trade the stock.
LabTurbo Biotech is classified in the Healthcare sector. On ROE, it currently shows -16.97% versus a sector average near -100.59%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing 7725.TWO with unrelated industries.